The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Open accessAbstract
Slowing Brain Disease with Gene Therapy: X-linked adrenoleukodystrophy (ALD), the hereditary brain demyelinating disorder that was featured in the movie “ Lorenzo's Oil ,” is typically treated by transplantation of bone marrow from matched donors. This treatment slows progression of the disease by introducing cells that differentiate into myelin-producing cells. Cartier et al. (p. 818 ; see Perspective by Naldini ) tested an alternative gene therapy–based approach in two young patients without matched donors. A lentiviral vector was used to introduce a wild-type copy of the ALD gene into the patients' hematopoietic stem cells ex vivo. The modified cells were then infused back into the patients. Expression of the transferred gene was still detectable in the patients' blood cells 2 years later, and both patients showed neurological improvement and a delay in disease progression comparable to that seen with bone marrow transplants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Expansions of cells with a common integration site were observed in a gene therapy trial using lentiviral vectors for adrenoleukodystrophy [51].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [51]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gene therapy is a cutting-edge approach that has shown potential in various genetic disorders, including X-ALD.”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Early-stage treatment of childhood cerebral ALD with hematopoietic stem cell transplantation and, more recently, gene therapy can arrest disease progression if performed in the window of opportunity when the MRI is abnormal but neurological symptoms are not yet apparent [7,38,43,44,45,46,47,48,49,50].”
From Structure and Function of the ABCD1 Variant Database: 20 Years, 940 Pathogenic Variants, and 3400 Cases of Adrenoleukodystrophy (2022) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“A lentiviral vector has been used to introduce a wild-type copy of the ABCD1 gene into the patients’ hematopoietic stem cells ex vivo. Subsequently, the genetically modified cells have been reintroduced into the patients (48).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“The positive results of HSC transplantation into cALD patients [24,356] indicated a role for brain microglia because microglia were thought to originate in bone marrow at that time [357].”
From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [356]
In the citing paper
“In ALD, phagocytes derived from autologous bone marrow transplants likely elicit their beneficial effects by replacing mutant microglia, as they stall terminal neuro-inflammation and demyelination 42.”
From Efficient derivation of microglia-like cells from human pluripotent stem cells (2016) · cites this paper as [42]
In the citing paper
“Allogenic hematopoietic stem cell transplantation [145,146] and autologous stem cell-based gene therapy [147] can arrest the inflammatory demyelinating process with a typical delay of 12–18 months, which has been attributed to the slow replacement of microglia with bone marrow-derived phagocytes [147,148].”
From Peroxisomes in brain development and function (2016) · cites this paper as [147]
In the citing paper
“This is strongly supported by the fact that both allogeneic hematopoietic stem cell (HSC) transplantation and autologous HSC gene therapy are very effective in arresting and even reversing neuroinflammatory cerebral ALD, provided that the procedure is performed at an early stage [101,102].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [102]
In the citing paper
“In 2009, autologous HSCT was demonstrated to be successful to halt cerebral demyelination in two boys with no compatible donors who received their own genetically corrected stem cells [ 82 ].”
From Peroxisomal ABC Transporters: An Update (2021) · cites this paper as [82]
In the citing paper
“These promising results suggest that such a therapeutic strategy may be as effective as allogeneic HSCT.”
From Peroxisomal ABC Transporters: An Update (2021) · cites this paper as [82]
In the citing paper
“the CD34+ PBMCs (lymphoid and myeloid progenitors) transduced with normal ABCD1 can efficiently correct the clinical phenotype of the X-ALD patients [ 82 ]”
From Peroxisomal ABC Transporters: An Update (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana, M., Hacein‐Bey‐Abina, S., Basile, G. D. S., Gross, F., Yvon, E. S., Nusbaum, P., Selz, F., Hue, C., Dogniaux, S., Casanova, J., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,685
Self-citationProjection of an Immunological Self Shadow Within the Thymus by the Aire Protein
Anderson, M. S., Venanzi, E. S., Klein, L., Chen, Z.-B., Berzins, S., Turley, S., von Boehmer, H., Bronson, R., Dierich, A., Benoist, C., et al. (2002) · Science · doi:10.1126/science.1075958 · Cited by 2,582
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
van Gent, R. N., Siem, D., van Middelkoop, M., van Os, A. G., Bierma‐Zeinstra, S., & Koes, B. W. (2007) · British Journal of Sports Medicine · doi:10.1136/bjsm.2006.033548 · Cited by 1,505
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M., Glorioso, J., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,444
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Loes D. J., et al.., Am. J. Neuroradiol. 15, 1761 (1994).7847225
Cited by
Sorted by citations
Items 501–600 of 1,000
Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy
Suerth, J. D., Labenski, V., & Schambach, A. (2014) · Viruses · doi:10.3390/v6124811 · Cited by 35
“…engineered cells into patients suffering from inherited diseases, e.g., from severe combined immunodeficiency [130–132], Wiskott-Aldrich syndrome [24,133], chronic granulomatous disease [19,20], adrenoleukodystrophy [134] and metachromatic leukodystrophy [135], or from cancer (examples below).”
BackgroundCombining Gene and Stem Cell Therapy for Peripheral Nerve Tissue Engineering
Busuttil, F., Rahim, A. A., & Phillips, J. B. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0188 · Cited by 34
“Lentiviral vectors have been used in a range of successful life-saving gene therapy clinical trials for a number of conditions such as X-linked severe combined immuno-deficiency [58] and X-linked adrenoleukodystrophy [49].”
Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy
Jang, Y., Kim, Y., Wielgosz, M. M., Ferrara, F., Ma, Z., Condori, J., Palmer, L. E., Zhao, X., Kang, G., Rawlings, D. J., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0150-z · Cited by 35
“no selective growth advantage in vivo [4, 14].”
Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Yoder, K. E., Rabe, A. J., Fishel, R. A., & Larue, R. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662331 · Cited by 37
Zheng, D., Dan, Y., Yang, S., Liu, G., Shao, Z., Cao, Y., Xiao, B., Liu, X., Wu, S., Zhang, T., et al. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.09.030 · Cited by 37
A Review of Gene Therapy in Canine and Feline Models of Lysosomal Storage Disorders
Bradbury, A. M., Gurda, B. L., Casal, M. L., Ponder, K. P., Vite, C. H., & Haskins, M. E. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.002 · Cited by 36
“129 Large animal models of LSDs have been paramount to the development of effective gene therapy protocols.”
Johnston, J. M., Denning, G., Doering, C. B., & Spencer, H. T. (2012) · Gene Therapy · doi:10.1038/gt.2012.76 · Cited by 34
Xu, C., Sun, Y., Wang, Y., Yan, Y., Shi, Z.-J., Chen, L., Han, L., Lü, S., Zhu, M., Su, C., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.009 · Cited by 35
Adeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous system
Blessing, D., & Déglon, N. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.004 · Cited by 36
Brain disorders and psychopathology
Heyman, I., Skuse, D., & Goodman, R. (2015) · Wiley eBooks · doi:10.1002/9781118381953.ch31 · Cited by 35
Bell, J. B., Aronovich, E. L., Schreifels, J. M., Beadnell, T. C., & Hackett, P. B. (2010) · Molecular Therapy · doi:10.1038/mt.2010.152 · Cited by 45
Solving the Problem of γ-Retroviral Vectors Containing Long Terminal Repeats
Persons, D. A., & Baum, C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.305 · Cited by 34
Mitchell, R., Nivison‐Smith, I., Anazodo, A. C., Tiedemann, K., Shaw, P. J., Teague, L. R., Fraser, C., Carter, T. L., Tapp, H., Alvaro, F., et al. (2013) · Pediatric Transplantation · doi:10.1111/petr.12109 · Cited by 33
“Total number of patients 53 Recipient sex Male 36 (68) Female 17 (32) Year of transplant 1992–1999 11 (21) 2000–2008 42 (79) Indication for transplant Hurler syndrome/mucopolysaccharidosis 25 (47) ALD 15 (28) MLD 9 (17) Aspartylglucosaminuria 3 (6) Mannosidosis 1 (2) Conditioning regimen Bu + Cy 29 (55) Bu + Cy + othe…”
BackgroundDeakin, C. T., Deakin, J. J., Ginn, S. L., Young, P. E., Humphreys, D. T., Suter, C. M., Alexander, I. E., & Hallwirth, C. V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku607 · Cited by 34
Chick, H. E., Nowrouzi, A., Fronza, R., McDonald, R. A., Kane, N. M., Alba, R., Delles, C., Sessa, W. C., Schmidt, M., Thrasher, A. J., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.042 · Cited by 34
“Although ICLV vectors have been shown to be intrinsically less prone to insertional mutagenesis (Montini et al., 2006; Cartier et al., 2009; Modlich et al., 2009; Montini et al., 2009; Bartholomae et al., 2011; Biffi et al., 2011; Nowrouzi et al., 2011”
Self-citationRecent Advances in Biomaterials for Tissue Engineering and Controlled Drug Delivery
Hélary, C., & Desimone, M. F. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101607150427112208 · Cited by 34
Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency
Tran, R., Myers, D. R., Denning, G., Shields, J. E., Lytle, A. M., Alrowais, H., Qiu, Y., Sakurai, Y., Li, W. C., Brand, O., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.002 · Cited by 34
Glial cells in the driver seat of leukodystrophy pathogenesis
Garcia, L., Hacker, J. L., Sase, S., Adang, L. A., & Almad, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105087 · Cited by 34
Skeate, J. G., Pomeroy, E. J., Slipek, N. J., Jones, B. J., Wick, B. J., Chang, J., Lahr, W. S., Stelljes, E. M., Patrinostro, X., Barnes, B., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.024 · Cited by 32
HIV-derived vectors for therapy and vaccination against HIV
Nunzio, F. D., Félix, T., Arhel, N. J., Nisole, S., Charneau, P., & Beignon, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.089 · Cited by 34
“LVs have been successfully used in gene therapy clinical trials, such as for treatment of adrenoleukodystrophy and -thalassaemia [31,32].”
Lentiviral vectors for immunization: an inflammatory field
Pincha, M., Sundarasetty, B. S., & Stripecke, R. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.9 · Cited by 33
Amphiphilic Oligoethyleneimine−β-Cyclodextrin “Click” Clusters for Enhanced DNA Delivery
Martínez, Á., Bienvenu, C., Blanco, J. L. J., Vierling, P., Mellet, C. O., Fernández, J. M. G., & Giorgio, C. D. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo400993y · Cited by 36
Groh, J., & Martini, R. (2017) · Glia · doi:10.1002/glia.23162 · Cited by 32
“Of note, hematopoietic stem cell transplantation in humans can mitigate inflammation and clinical outcome and, thus, appears to be a potent therapy for the fatal, inflammation-driven disease form (Cartier et al., 2009).”
BackgroundOzog, S., Timberlake, N. D., Hermann, K. J., Garijo, O., Haworth, K. G., Shi, G., Glinkerman, C. M., Schefter, L. E., D'Souza, S. S., Simpson, E., et al. (2019) · Blood · doi:10.1182/blood.2019000040 · Cited by 33
Efficient Nuclease-Directed Integration of Lentivirus Vectors into the Human Ribosomal DNA Locus
Schenkwein, D., Afzal, S., Nousiainen, A., Schmidt, M., & Ylä‐Herttuala, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.019 · Cited by 32
Self-citationKim, H. S., Hwang, G., Lee, H. K., Bae, T., Park, S.-H., Kim, Y. J., Lee, S., Park, J.-H., Bae, S., & Hur, J. K. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.012 · Cited by 35
Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
Weinhofer, I., Rommer, P. S., Gleiß, A., Ponleitner, M., Zierfuss, B., Waidhofer‐Söllner, P., Fourcade, S., Grabmeier‐Pfistershammer, K., Reinert, M., Göpfert, J. C., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104781 · Cited by 35
Self-citationCell and Gene Therapy for Friedreich Ataxia: Progress to Date
Evans‐Galea, M. V., Pébay, A., Dottori, M., Corben, L. A., Ong, S. H., Lockhart, P. J., & Delatycki, M. B. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.180 · Cited by 33
“Common integration sites identified postcorrection were because of a benign integration bias and not oncogenic selection (Cartier al ., 2009; Biffi et al ., 2011), indicating SIN lentiviral vectors have a superior safety profile over conventional oncore-troviral vectors (such as those used in the…”
Lau, A. A., Hannouche, H., Rozaklis, T., Hassiotis, S., Hopwood, J. J., & Hemsley, K. M. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.07.024 · Cited by 32
Genetically engineered immune privileged Sertoli cells
Kaur, G., Long, C. R., & Dufour, J. M. (2012) · Spermatogenesis · doi:10.4161/spmg.19119 · Cited by 32
Peptide nanofibrils as enhancers of retroviral gene transfer
Meier, C. A., Weil, T., Kirchhoff, F., & Münch, J. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1275 · Cited by 34
Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer’s disease
Magga, J. M., Savchenko, E., Malm, T., Rõlova, T., Pollari, E., Valonen, P. K., Lehtonen, Š., Jantunen, E., Aarnio, J., Lehenkari, P. P., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01390.x · Cited by 33
“Recently, lentivirally mediated gene therapy was shown to provide clinical benefits in an inheritable fatal demyelinating disease X-linked adrenoleukodystrophy [64].”
BackgroundGene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point of View
Cavazzana, M., Ribeil, J., Lagresle‐Peyrou, C., & André‐Schmutz, I. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0230 · Cited by 34
“CONCISE REVIEW Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow’s Point of View Marina Cavazzana,1–4 Jean-Antoine Ribeil,1 Chantal Lagresle-Peyrou,2–4 and Isabelle André-Schmutz2–4 When considering inherited diseases that can be treated by gene transfer into hematopoietic stem cells (HSCs), there…”
MethodInfluentialWanders, R. J. A. (2018) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2018.02.001 · Cited by 33
Iijima, O., Miyake, K., Watanabe, A., Miyake, N., Igarashi, T., Kanokoda, C., Nakamura-Takahashi, A., Kinoshita, H., Noguchi, T., Abe, S., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.078 · Cited by 31
Progress in gene therapy for primary immunodeficiencies using lentiviral vectors
Sauer, A. V., Lorenzo, B. D., Carriglio, N., & Aiuti, A. (2014) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000114 · Cited by 32
Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β‐thalassemia
Sadelain, M., Rivière, I., Wang, X., Boulad, F., Prockop, S. E., Giardina, P. J., Maggio, A., Galanello, R., Locatelli, F., & Yannaki, E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05597.x · Cited by 34
Myelin lesions associated with lysosomal and peroxisomal disorders
Faust, P. L., Kaye, E. M., & Powers, J. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.127 · Cited by 31
Gene therapies for inherited skin disorders
Abdul‐Wahab, A., Qasim, W., & McGrath, J. A. (2014) · Seminars in Cutaneous Medicine and Surgery · doi:10.12788/j.sder.0085 · Cited by 31
Gene therapy for lysosomal storage diseases and peroxisomal diseases
Ohashi, T. (2019) · Journal of Human Genetics · doi:10.1038/s10038-018-0537-5 · Cited by 31
The recombinase activating genes: architects of immune diversity during lymphocyte development
Braams, M., Pike‐Overzet, K., & Staal, F. J. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210818 · Cited by 33
Molecular and clinical findings and diagnostic flowchart of peroxisomal diseases
Shimozawa, N. (2011) · Brain and Development · doi:10.1016/j.braindev.2011.03.004 · Cited by 31
“Newborn screening may be a potential method to discover pre-symptomatic ALD patients and female carriers widely [14], and recently, hematopoietic stem cell gene therapy was shown to arrest progression in patients with the early stages of cerebral form of ALD [15].”
MethodRousseau, J., Gioia, R., Layrolle, P., Lieubeau, B., Heymann, D., Rossi, A., Marini, J. C., Trichet, V., & Forlino, A. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.198 · Cited by 31
Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo
Delzor, A., Escartin, C., & Déglon, N. (2013) · Current Drug Targets · doi:10.2174/13894501113146660213 · Cited by 31
Is Human Enhancement also a Personal Matter?
Menuz, V., Hurlimann, T., & Godard, B. (2011) · Science and Engineering Ethics · doi:10.1007/s11948-011-9294-y · Cited by 31
Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS‐275
Zierfuss, B., Weinhofer, I., Buda, A., Popitsch, N. P., Hess, L., Moos, V., Hametner, S., Kemp, S., Köhler, W., Forss‐Petter, S., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51200 · Cited by 30
Loeb, A. M., Pattwell, S. S., Meshinchi, S., Bedalov, A., & Loeb, K. R. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010409 · Cited by 32
Tubsuwan, A., Abed, S., Deichmann, A., Kardel, M., Bartholomae, C. C., Cheung, A. M. S., Nègre, O., Kadri, Z., Fucharoen, S., Kalle, C. V., et al. (2013) · Stem Cells · doi:10.1002/stem.1436 · Cited by 30
Self-citationThe genomic risk of somatic gene therapy
Kustikova, O. S., Brugman, M. H., & Baum, C. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.06.003 · Cited by 30
Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins
Enkirch, T., Kneissl, S., Hoyler, B., Ungerechts, G., Stremmel, W., Buchholz, C. J., & Springfeld, C. (2012) · Gene Therapy · doi:10.1038/gt.2011.209 · Cited by 34
Newborn Bloodspot Screening for Lysosomal Storage Disorders
Zhou, H., Fernhoff, P. M., & Vogt, R. F. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.02.026 · Cited by 30
Recent challenges and advances in genetically-engineered cell therapy
Yong, S., Chung, J. Y., Song, Y., & Kim, Y. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0381-1 · Cited by 30
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
Cantore, A., & Naldini, L. (2020) · Haemophilia · doi:10.1111/hae.14056 · Cited by 30
Gene therapy for inherited metabolic diseases
Yılmaz, B. Ş., Gurung, S., Perocheau, D. P. B., Counsell, J. R., & Baruteau, J. (2020) · PubMed Central · doi:10.34763/jmotherandchild.20202402si.2004.000009 · Cited by 31
Paugh, B. S., Baranyi, L., Roy, A. J., He, H., Harris, L. N., Cole, K. D., Artlip, M., Raimund, C., Langan, P. S., Jana, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79698-w · Cited by 29
Gene Therapy of Sphingolipid Metabolic Disorders
Shaimardanova, A. A., Solovyeva, V. V., Issa, S. S., & Rizvanov, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043627 · Cited by 30
Gene and cell therapy based treatment strategies for inflammatory bowel diseases
van der Marel, S. (2011) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v2.i6.114 · Cited by 30
Engineering Stem Cells for Biomedical Applications
Yin, P. T., Han, E. X., & Lee, K. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400842 · Cited by 31
Torres‐Torronteras, J., Cabrera-Pérez, R., Barba, I., Costa, C., de Luna, N., Andreu, A. L., Barquinero, J., Hirano, M., Cámara, Y., & Martí, R. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.160 · Cited by 31
Yong, K. S. M., Keng, C. T., Tan, S. Q., Loh, E., Chang, K. T. E., Tan, T. C., Hong, W., & Chen, Q. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.40 · Cited by 29
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 31
Sakuma, T., Ravin, S. S. D., Tonne, J. M., Thatava, T., Ohmine, S., Takeuchi, Y., Malech, H. L., & Ikeda, Y. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.063 · Cited by 29
Keller, M. D., Notarangelo, L. D., & Malech, H. L. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy011 · Cited by 30
Integration of retroviral vectors
Gabriel, R., Schmidt, M., & Kalle, C. V. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.006 · Cited by 33
“Recently, HIV-1 based self-inactivating (SIN) lentiviral vectors have been successfully used to treat X-linked adrenoleukodystrophy [50] and betathalassaemia [51].”
MethodSelf-citationPreclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 31
Expression of Wild-Type Rp1 Protein in Rp1 Knock-in Mice Rescues the Retinal Degeneration Phenotype
Liu, Q., Collin, R. W. J., Cremers, F. P. M., den Hollander, A. I., van den Born, L. I., & Pierce, E. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043251 · Cited by 31
Jönsson, F., & Kreppel, F. (2017) · Virus Genes · doi:10.1007/s11262-017-1498-z · Cited by 28
X-linked adrenoleukodystrophy and primary adrenal insufficiency
Cappa, M., Todisco, T., & Bizzarri, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1309053 · Cited by 28
Arrayed lentiviral barcoding for quantification analysis of hematopoietic dynamics
Grosselin, J., Sii-Felice, K., Payen, E., Chrétien, S., Roux, D. T., & Leboulch, P. (2013) · Stem Cells · doi:10.1002/stem.1383 · Cited by 28
Self-citationLeukodystrophies in Children: Diagnosis, Care, and Treatment
Bonkowsky, J. L., Keller, S. R., Capal, J. K., Lotze, T. E., Shellhaas, R. A., Urion, D. K., Chen, E., Trotter, T. L., Berry, S. A., Burke, L. W., et al. (2021) · PEDIATRICS · doi:10.1542/peds.2021-053126 · Cited by 29
“78,79 A clinical trial of HSC-GT for the treatment of MLD was initiated in Milan, Italy, in 2010.”
Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies
Ma, C. Y., Li, C., Zhou, X., Zhang, Z., Jiang, H., Liu, H., Chen, H. J., Tse, H., Liao, C., & Lian, Q. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112214 · Cited by 31
Liang, Q., Catalano, F., Vlaar, E. C., Pijnenburg, J. M., Stok, M., van Helsdingen, Y., Vulto, A. G., van der Ploeg, A. T., van Til, N. P., & Pijnappel, W. W. M. P. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.010 · Cited by 28
Genome-Wide Analysis of Alpharetroviral Integration in Human Hematopoietic Stem/Progenitor Cells
Moiani, A., Suerth, J. D., Gandolfi, F., Rizzi, E., Severgnini, M., Bellis, G. D., Schambach, A., & Mavilio, F. (2014) · Genes · doi:10.3390/genes5020415 · Cited by 28
“Transplantation of hematopoietic stem cells genetically modified by retroviral vectors has proven its clinical efficacy in a number of seminal clinical trials for the treatment of severe monogenic disorders [1–8].”
BackgroundInsights into neurogenesis and aging: potential therapy for degenerative disease?
Marr, R. A., Thomas, R. M., & Peterso, D. A. (2010) · Future Neurology · doi:10.2217/fnl.10.33 · Cited by 29
Lentiviral vector interactions with the host cell
Borsotti, C., Borroni, E., & Follenzi, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.016 · Cited by 29
Innovative Treatments for Lysosomal Diseases
Cox, T. M. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.01.001 · Cited by 28
Vector Integration and Tumorigenesis
Kalle, C. V., Deichmann, A., & Schmidt, M. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2525 · Cited by 27
“This and the missing in vivo expansion of gene-corrected cells make lentiviral vectors promising vehicles for various transgenes (Cartier et al., 2009).”
Self-citationHistorical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy
Kohn, D. B. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.006 · Cited by 28
Fourcade, S., Goicoechea, L., Parameswaran, J., Schlüter, A., Launay, N., Ruíz, M., Seyer, A., Colsch, B., Calingasan, N. Y., Ferrer, I., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12869 · Cited by 28
“For the cerebral form of the disease, current therapeutic options are restricted to bone marrow transplantation (47) and for childhood cALD, hematopoietic stem cell gene therapy (5,12).”
BackgroundA primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 28
The transformative potential of HSC gene therapy as a genetic medicine
Sagoo, P., & Gaspar, H. B. (2021) · Gene Therapy · doi:10.1038/s41434-021-00261-x · Cited by 27
“HSC gene therapy treatments Since the first clinical trials with LV-mediated HSC GT in the mid-2000s [67, 68], this approach has now been employed safely and effectively across numerous different primary immune deficiencies, hemoglobinopathies, and storage and metabolic diseases, providing proof of its transformative…”
BackgroundMagnon, C., Lucas, D., & Frenette, P. S. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-145-1_1 · Cited by 27
Tracking gene and cell fate for therapeutic gain
Kooreman, N. G., Ransohoff, J. D., & Wu, J. C. (2014) · Nature Materials · doi:10.1038/nmat3868 · Cited by 28
X-linked adrenoleukodystrophy: Diagnostic and follow-up system in Japan
Shimozawa, N., Honda, A., Kajiwara, N., Kozawa, S., Nagase, T., Takemoto, Y., & Suzuki, Y. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2010.139 · Cited by 27
Optimization of Magnetic Nanoparticle-Assisted Lentiviral Gene Transfer
Trueck, C., Zimmermann, K., Mykhaylyk, O. M., Anton, M., Vosen, S., Wenzel, D., Fleischmann, B. K., & Pfeifer, A. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0660-x · Cited by 26
Cornils, K., Bartholomae, C. C., Thielecke, L., Lange, C., Arens, A., Glauche, I., Mock, U., Riecken, K., Gerdes, S., Kalle, C. V., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.09.003 · Cited by 26
Self-citationTowards Improved shRNA and miRNA Reagents as Inhibitors of HIV1 Replication
Berkhout, B., & Liu, Y. P. (2014) · Future Microbiology · doi:10.2217/fmb.14.5 · Cited by 26
Grinshpun, A., Condiotti, R., Waddington, S. N., Peer, M., Zeig, E., Peretz, S., Simerzin, A., CHOU, J. Y., Pan, C., Giladi, H., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.119 · Cited by 29
Bone Marrow Gene Therapy for HIV/AIDS
Herrera-Carrillo, E., & Berkhout, B. (2015) · Viruses · doi:10.3390/v7072804 · Cited by 27
“There is growing evidence that the third generation lentiviral vector, which allows stable integration of the therapeutic gene, can be used safely [144–146].”
BackgroundHematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches
Lamsfus‐Calle, A., Daniel-Moreno, A., Ureña-Bailén, G., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100641 · Cited by 29
Hong, S.-A., Seo, J. H., Wi, S., Jung, E. S., Yu, J., Hwang, G., Yu, J. H., Baek, A., Park, S., Bae, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.022 · Cited by 27
Brendel, C., Haenseler, W., Wohlgensinger, V., Bianchi, M., Tokmak, S., Chen-Wichmann, L., Kuzmenko, E. S., Cesarovic, N., Nicholls, F., Reichenbach, J., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.157 · Cited by 26
“…benefit for treated patients has been continuously growing (Aiuti et al. , 2002; Mavilio et al. , 2006; Morgan et al. , 2006; Ott et al. , 2006; Kaplitt et al. , 2007; Bainbridge et al. , 2008; Cartier et al. , 2009; Boztug et al. , 2010; Cavazzana-Calvo et al. , 2010; Porter et al. , 2011).”
The use of cell-delivered gene therapy for the treatment of HIV/AIDS
Symonds, G. P., Johnstone, H. A., Millington, M., Boyd, M. P., Burke, B. P., & Breton, L. (2010) · Immunologic Research · doi:10.1007/s12026-010-8169-7 · Cited by 26
Giry-Laterrière, M., Cherpin, O., Kim, Y. S., Jensen, J. N., & Salmon, P. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.179 · Cited by 26
Abel, U., Deichmann, A., Nowrouzi, A., Gabriel, R., Bartholomae, C., Glimm, H., von Kalle, C., & Schmidt, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024247 · Cited by 24
“In a recently carried out hematopoietic stem cell gene therapy of ALD in two patients”
BackgroundSelf-citationKays, S.-K., Kaufmann, K. B., Abel, T., Brendel, C., Bonig, H. B., Grez, M., Buchholz, C. J., & Kneissl, S. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0455 · Cited by 28
“…detected in the colonies formed or in the transplantedmice must havebeenderived from CD105 + HSCs. Lentiviral vectors equipped with the VSVG envelope protein are today’s standard for clinical trials with patients suffering from genetic diseases that can be treated by HSC-based gene therapy [30–32].”
van der Knaap, M. S., Wolf, N. I., & Heine, V. M. (2016) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000289 · Cited by 26
Novel GP64 envelope variants for improved delivery to human airway epithelial cells
Sinn, P. L., Hwang, B.-Y., Li, N., Ortiz, J. L. S., Shirazi, E., Parekh, K. R., Cooney, A. L., Schaffer, D. V., & McCray, P. B. (2017) · Gene Therapy · doi:10.1038/gt.2017.78 · Cited by 25
Potential use of stem cells as a therapy for cystinosis
Rocca, C. J., & Cherqui, S. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3974-7 · Cited by 26
“Autologous CD34 cells transduced with a SIN-LV strategy was also successful for the treatment of X-linked cerebral adrenoleukodystrophy (ALD) [72, 73].”
BackgroundInfluentialImmunoresponse to Gene-Modified Hematopoietic Stem Cells
Drysdale, C. M., Tisdale, J. F., & Uchida, N. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.010 · Cited by 28
Metadata
- Authors
- Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme, C., Lahlou, N., Lefrère, F., Blanche, S., Audit, M., Payen, E., Leboulch, P., l’Homme, B., Bougnères, P., Von Kalle, C., Fischer, A., Cavazzana-Calvo, M., & Aubourg, P.
- Affiliations
- Inserm (FR)
- Department of Biotherapy, Hôpital Necker-Enfants Malades, 75743 Paris, France.
- German Cancer Research Center (DE)
- 117 Southwest 72nd Place, Gainesville, FL 32608, USA.
- Hôpital Necker-Enfants Malades (FR)
- Nature Publishing Group, New York, NY 10013–1917, USA.
- 13687 Quinton Road, San Diego, CA 92129, USA.
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Saint-Vincent-de-Paul (FR)
- GenoSafe (FR)
- Brigham and Women's Hospital (US)
- Department of Pediatric Endocrinology and Neurology, Hôpital Saint-Vincent de Paul, Assistance Publique–Hôpitaux de Paris, 82 Avenue Denfert-Rochereau, 75674 Paris, France.
- National Center for Tumor Diseases and German Cancer Research Center (Deutsches Krebsforschungszentrum), 69120 Heidelberg, Germany.
- Corresponding author
- Cartier, Nathalie
- Aubourg, Patrick
- ORCID
- Venue
- Science
- Published
- 2009-11-06
- Volume
- 326
- Issue
- 5954
- Pages
- 818-823
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141570423
- Cited by
- 1,508
- References
- 40
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 54 · 2023: 50 · 2022: 62 · 2021: 56 · 2020: 71 · 2019: 61 · 2018: 76 · 2017: 96 · 2016: 98 · 2015: 107 · 2014: 130 · 2013: 137 · 2012: 139
- FWCI
- 84.34
- Type
- journal article
- Language
- en
- Open access
- green
- cea.hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (SPP 1230)
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Association Européenne contre les Leucodystrophies
- Assistance publique-Hôpitaux de Paris
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- X-linked adrenoleukodystrophy, hematopoietic stem cell gene therapy, lentiviral vectors, ABCD1 gene, myeloablative conditioning, demyelination
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, Member 1, Adrenoleukodystrophy, Animals, Brain, Cell Differentiation, Child, Fatty Acids, Female, Genetic Vectors, Hematopoiesis, Hematopoietic Stem Cells, Humans, Leukocytes, Mononuclear, Male, Transduction, Genetic, Transplantation, Autologous, Genetic Therapy, HIV-1, Gene Expression, Virus Integration, Microglia, Hematopoietic Stem Cell Transplantation, Disease Progression, ATP-Binding Cassette Transporters, Cell Lineage, Transplantation Conditioning, Myeloablative Agonists, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
